ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi’s Zika vaccine gets funding

by Lisa M. Jarvis
October 3, 2016 | APPEARED IN VOLUME 94, ISSUE 39

The U.S. Biomedical Advanced Research & Development Authority will give Sanofi $43.2 million to support the manufacturing of a Zika vaccine. In July, the Walter Reed Army Institute of Research transferred its technology for a purified, inactivated Zika virus (ZPIV) vaccine to Sanofi, which agreed to commercialize it. The cash from BARDA will allow Sanofi to improve yields and make the vaccine for Phase II trials. Walter Reed and NIH are conducting Phase I trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment